In a rare rebuke, FDA refuses to fully review Aeglea’s rare disease drug applicationnews2022-06-02T19:54:11+00:00June 2nd, 2022|FierceBiotech|
UPDATE: Bristol Myers triples-down on Immatics, bringing deal to $4.2B total biobucks. Why not just buy it?news2022-06-02T15:00:50+00:00June 2nd, 2022|FierceBiotech|
Centessa dumps top program after evidence of tolerability issues stunt market potentialnews2022-06-02T14:44:02+00:00June 2nd, 2022|FierceBiotech|
Oncology biotech Atreca pulled into industry’s layoff whirlpool, cuts 25% of staffnews2022-06-02T14:37:13+00:00June 2nd, 2022|FierceBiotech|
Enochian CEO, facing short-seller attack, tries to distance biotech from co-founder arrested in murder-for-hire-plotnews2022-06-02T13:42:10+00:00June 2nd, 2022|FierceBiotech|
PARADIGME shift: Nordic Nanovector reviews stuttering cancer trial as enrollment grinds to a haltnews2022-06-02T11:24:12+00:00June 2nd, 2022|FierceBiotech|
